Loading...
Ons wil graag hê dat jy deel word van ons gemeenskap. Sluit aan by ons Discord om met ons en ander lede te skakel!
- Ticker
- CRMD
- Price
- 14.35
- Stock movement up
- +0.37 (2.65%)
- Company name
- CorMedix Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markkapitalisasie
- 870.72M
- Ondernemingswaarde
- 854.31M
- Prys/Verkope
- 69.29
- Prys/Boek
- 14.83
- Dividendopbrengs
- -
- Dividendgroei
- -
- Groei jare
- -
- FCF uitbetaling
- -
- Agterlopende P/E
- -
- Volgende P/E
- 29.90
- PEG
- -
- EPS groei
- -9.58%
- 1 jaar opbrengs
- 170.75%
- 3 jaar opbrengs
- 68.49%
- 5 jaar opbrengs
- 21.28%
- 10 jaar opbrengs
- -8.45%
Laaste opgedateer: 2025-06-10
CorMedix (CRMD) is a buy with its financial turnaround, robust growth, and first-mover advantage in the US dialysis market. See more here.
5 Junie 2025
iO Charts is a Seeking Alpha partner
CorMedix boasts a robust balance sheet, no long-term debt, and is projected to deliver substantial earnings and revenue growth through FY2026. Learn more on CRMD stock here.
4 Junie 2025
iO Charts is a Seeking Alpha partner
DIVIDENDE
CRMD betaal nie dividende nie of geen data is ontvang nie
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
WAARDERING
Waarderingsverhoudings
Loading...
Waarderingsverhoudings gegewens
| Agterlopende P/E | - |
| Prys tot OCF | - |
| Prys tot FCF | - |
| Prys tot EBITDA | - |
| EV tot EBITDA | - |
Waardering (Verkope/Boekwaarde)
Loading...
Waardering (Verkope/Boekwaarde) gegewens
| Prys tot verkope | 69.29 |
| Prys tot Boekwaarde | 14.83 |
| EV tot verkope | 67.98 |
CorMedix, Inc. (NASDAQ:CRMD) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ETCompany ParticipantsDan Ferry – LifeSci AdvisorsJoe Todisco – Chief...
6 Mei 2025
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANSIËLE
Per aandeel
Loading...
Per aandeel gegewens
| Huidige aandeeltelling | 60.68M |
| EPS (TTM) | -47.94 |
| FCF per aandeel (TTM) | -0.95 |
Inkomstestaat
Loading...
Inkomstestaat gegewens
| Inkomste (TTM) | 12.57M |
| Bruto wins (TTM) | 10.50M |
| Bedryfsinkomste (TTM) | -50.96M |
| Netto inkomste (TTM) | -2.82B |
| EPS (TTM) | -47.94 |
| EPS (1j vorentoe) | 0.48 |
Marges
Loading...
Marges gegewens
| Bruto marge (TTM) | 83.54% |
| Bedryfsmarge (TTM) | -405.54% |
| Winsgrens (TTM) | -22442.36% |
Balansstaat
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Balansstaat gegewens
| Kontant | 35.29M |
| Netto debiteure | 17.39M |
| Totale bedryfsbates | 73.15M |
| Klandisiewaarde | 0.00 |
| Ontasbare bates | 1.90M |
| Eiendom, aanleg en toerusting | 2.43M |
| Totale bates | 77.59M |
| Rekeninge betaalbaar | 1.34M |
| Kort/huidige langtermynskuld | 556.42K |
| Totale bedryfslaste | 18.48M |
| Totale laste | 18.87M |
| Aandeelhouersbelang | 58.71M |
| Netto tasbare bates | 0.00 |
Kontantvloei
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Kontantvloei gegewens
| Bedryfskontantvloei (TTM) | -55.75M |
| Kapitale uitgawes (TTM) | 401.79K |
| Vrye kontantvloei (TTM) | -56.15M |
| Dividende betaal (TTM) | 0.00 |
Finansiële opbrengste
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Finansiële opbrengste gegewens
| Opbrengs op ekwiteit | -4803.40% |
| Opbrengs op bates | -3634.90% |
| Opbrengs op belegde kapitaal | -4790.06% |
| Kontant opbrengs op belegde kapitaal | -95.37% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
AANDELE INLIGTING
Aandele grafiek
Loading...
Aandele prys data
| Open | 13.98 |
| Daaglikse hoog | 14.46 |
| Daaglikse laag | 13.83 |
| Daaglikse volume | 1.74M |
| Hoogtepunt van alle tye | 49.35 |
| 1j analiseraaming | 16.25 |
| Beta | 1.58 |
| EPS (TTM) | -47.94 |
| Dividend per aandeel | - |
| Ex-dividend datum | - |
| Volgende verdienste datum | - |
Afwaartse potensiaal
Loading...
Afwaartse potensiaal gegewens
| CRMD | S&P500 | |
| Huidige prysdaling vanaf die hoogste punt van alle tye | -70.92% | -2.16% |
| Hoogste prysdaling | -98.24% | -56.47% |
| Datum van hoogste daling | 22 May 2018 | 9 Mar 2009 |
| Gemiddelde daling vanaf hoogtepunt | -76.89% | -11.05% |
| Gemiddelde tyd tot nuwe hoogtepunt | 179 days | 12 days |
| Maksimum tyd tot nuwe hoogtepunt | 2563 days | 1805 days |
CorMedix's DefenCath cuts infection risk by 71% for dialysis patients. Despite its potential, CRMD stock is fairly priced post-FDA approval. Read here for more.
28 Maart 2025
iO Charts is a Seeking Alpha partner
CorMedix Inc.'s DefenCath reduces catheter infections by 71%, but the limited market potential challenges long-term adoption. Read more about CRMD stock here.
26 Maart 2025
iO Charts is a Seeking Alpha partner
MAATSKAPPY BESONDERHEDE
Markkapitalisasie
870.72M
Markkapitalisasie kategorie
Small-cap
Beskrywing
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Werknemers
82
Webwerf
Beleggerverhoudings
-
SEC lêers
CEO
Mohammed Khoso Baluch
Land
USA
Stad
Berkeley Heights
Aandele tipe
Common stock
CCC status
-
Dividendfrekwensie
-
GEBEURE EN AANBIEDINGS
GebeureAanbiedings
Loading...
iO Charts is a Seeking Alpha partner
CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ETCompany ParticipantsDan Ferry - Managing Director, LifeSci AdvisorsJoe...
25 Maart 2025
iO Charts is a Seeking Alpha partner
VERSTAAN DIE BESIGHEID
Loading...
MAATSKAPPY NUUS
Seeking AlphaPersvrystellings
CorMedix Inc.'s DefenCath shows considerable promise in reducing catheter-related bloodstream infections. Click here for this CRMD update.
7 Januarie 2025
CorMedix Inc. (NASDAQ:CRMD) Q3 2024 Earnings Call October 30, 2024 8:30 AM ETCompany ParticipantsDan Ferry - Investor RelationsJoe Todisco - Chief Executive...
30 Oktober 2024
CorMedix addresses catheter infections with its new solution, DefenCath. Read more about CRMD stock’s potential as the company enters commercialization.
28 Oktober 2024
Read more on CorMedix (CRMD)'s FDA-approved DefenCath and its potential in the CRBSI market, but be cautious of stock spikes driven by recent launch.
19 Oktober 2024
iO Charts is a Seeking Alpha partnerVolgende bladsy